Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urgency Frequency Clear all
Completed Phase 4 Interventional

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

NCT00143481
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
58
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 11, 2026, 8:41 AM EDT
Not listed Phase 3 Interventional

Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms

NCT00094874
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Acupuncture
Procedure
Lead sponsor
The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 11, 2026, 8:41 AM EDT
Completed No phase listed Observational

Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders

NCT00667550
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Colorectal Disorders
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Sep 11, 2026, 8:41 AM EDT
Terminated Not applicable Interventional

Pelvic Floor Muscle Training With Leva System for Urge Incontinence

NCT03923348
View directory record Official record
Conditions
Overactive Bladder, Urge Urinary Incontinence, Mixed Urinary Incontinence
Interventions
Leva device
Device
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 11, 2026, 8:41 AM EDT
Terminated Phase 2 Interventional Results available

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

NCT00517868
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Glendora, California • San Diego, California • Cartersville, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome

NCT00131573
View directory record Official record
Conditions
Overactive Bladder
Interventions
bion
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Tucson, Arizona • Stanford, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)

NCT03131544
View directory record Official record
Conditions
BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
Interventions
MRI Guided Transrectal Periuretheral Transitional Zone Ablation
Device
Lead sponsor
Prostate Laser Center, PLLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00914667
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
warfarin, Warfarin plus Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 4 Interventional

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

NCT00230789
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Not applicable Interventional Results available

InterStim Therapy Programming Study

NCT01009333
View directory record Official record
Conditions
Urgency Frequency, Urinary Urge Incontinence
Interventions
InterStim Therapy at rate 5.2 Hz, InterStim Therapy at rate 14 Hz, InterStim Therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)

NCT01125722
View directory record Official record
Conditions
Overactive Bladder
Interventions
Non-invasive neurostimulation device
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Royal Oak, Michigan • Lawrenceville, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 4 Interventional

Detrol LA In Men With Overactive Bladder.

NCT00282932
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Detrol LA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 11, 2026, 8:41 AM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions
Axonics SNM System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

NCT01369485
View directory record Official record
Conditions
Overactive Bladder
Interventions
(VERV™ System), Sham version of (VERV™ System)
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 11, 2026, 8:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

OAB and the Microbiome

NCT04831801
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 11, 2026, 8:41 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 11, 2026, 8:41 AM EDT
Recruiting No phase listed Observational

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00499317
View directory record Official record
Conditions
Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Phase 4 Interventional Results available

Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis

NCT01195116
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 11, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 11, 2026, 8:41 AM EDT
Terminated Phase 4 Interventional Results available

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

NCT01302938
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 11, 2026, 8:41 AM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

NCT04734106
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Desert Harvest Aloe Vera Capsules, Placebo Capsules
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 11, 2026, 8:41 AM EDT